Glancy | Jotup

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against 360 DigiTech, Inc. (QFIN)

Retrieved on:

Friday, July 30, 2021

Organizations, Lluís Companys, Limited liability partnership, Articles, Glancy, Class action, Surname

Key Points:

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
On this news, the Companys share price fell $7.12, or 21%, to close at $26.02 per share on July 8, 2021.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
Glancy Prongay & Murray LLP, Los Angeles

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Orphazyme A/S (ORPH)

Retrieved on:

Monday, July 26, 2021

Articles, Organizations, Business, ADSS, Initial public offering, Class action, Shareholder, Limited liability partnership, Glancy

Key Points:

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
In September 2020, Orphazyme completed its IPO, selling approximately 4 million ADSs at $11.00 per share.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
Glancy Prongay & Murray LLP, Los Angeles

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Athira Pharma, Inc. (ATHA)

Retrieved on:

Thursday, July 22, 2021

Limited liability partnership, Partnerships, Glancy, Surname, Names

Key Points:

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
Athira is a late-stage clinical biopharmaceutical company that is focused on developing small molecules to restore neuronal health and stop neurodegeneration.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
Glancy Prongay & Murray LLP, Los Angeles

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against RLX Technology Inc. (RLX)

Retrieved on:

Friday, July 16, 2021

ADSS, RLX, Initial public offering, Glancy, Surname, Names

Key Points:

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
In January 2021, RLX conducted its IPO, selling approximately 116.5 million ADSs) at $12 per ADS, raising approximately $1.4 billion in gross proceeds.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
Glancy Prongay & Murray LLP, Los Angeles

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Frequency Therapeutics, Inc. (FREQ)

Retrieved on:

Friday, July 16, 2021

Limited liability partnership, Partnerships, Glancy, Class action, Linehan, Surname, Names

Key Points:

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
Frequency Therapeutics has conducted several clinical studies evaluating the safety and effectiveness of FX-322, the most significant which was a Phase 2a study that began in October 2019.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
Glancy Prongay & Murray LLP, Los Angeles

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Athira Pharma, Inc. (ATHA)

Retrieved on:

Thursday, July 15, 2021

Limited liability partnership, Partnerships, Glancy, Surname, Names

Key Points:

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
Athira is a late-stage clinical biopharmaceutical company that is focused on developing small molecules to restore neuronal health and stop neurodegeneration.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
Glancy Prongay & Murray LLP, Los Angeles

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against James River Group Holdings, Ltd. (JRVR)

Retrieved on:

Wednesday, July 14, 2021

Legal, Professional services, Glancy, Surnames, Surname, Names

Key Points:

Glancy Prongay & Murray LLP (GPM) reminds investors of the upcoming September 7, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired James River Group Holdings, Ltd. (James River or the Company) (NASDAQ: JRVR ) common stock between August 1, 2019 and May 5, 2021, inclusive (the Class Period).
You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
On October 8, 2019, after the market closed, James River disclosed that it had delivered a notice of early cancellation of all policies issued to its largest customer, Rasier LLC.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Washington Prime Group, Inc. (WPG)

Retrieved on:

Monday, July 12, 2021

Limited liability partnership, Partnerships, Glancy, Class action, Surname, Names

Key Points:

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
The Company further advised that, in an event of default, certain counterparties to the senior notes could accelerate the outstanding indebtedness due .
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
Glancy Prongay & Murray LLP, Los Angeles

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Frequency Therapeutics, Inc. (FREQ)

Retrieved on:

Friday, July 9, 2021

Limited liability partnership, Partnerships, Glancy, Class action, Linehan, Surname, Names

Key Points:

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
Frequency Therapeutics has conducted several clinical studies evaluating the safety and effectiveness of FX-322, the most significant which was a Phase 2a study that began in October 2019.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
Glancy Prongay & Murray LLP, Los Angeles

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against RLX Technology Inc. (RLX)

Retrieved on:

Friday, July 9, 2021

ADSS, RLX, Initial public offering, Glancy, Surname, Names

Key Points:

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
In January 2021, RLX conducted its IPO, selling approximately 116.5 million ADSs) at $12 per ADS, raising approximately $1.4 billion in gross proceeds.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
Glancy Prongay & Murray LLP, Los Angeles